ARTV · XBRL financial data

Artiva Biotherapeutics financial statements, every quarter

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ARTV's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Revenue	0*	0*	0*	—	—	—	year only	—	—
Research and development	12,333	13,524	13,317*	17,052	17,861	17,633	16,994*	19,312	21,925
General and administrative	3,857	4,811	4,950*	5,119	4,949	5,264	4,938*	5,118	4,965
Total operating expenses	16,190	18,335	18,267*	22,171	22,810	22,897	21,932*	24,430	26,890
Operating income (loss)	(16,190)	(18,335)	(18,267)*	(22,171)	(22,810)	(22,897)	(21,932)*	(24,430)	(26,890)
Other income (expense)	23	(6)	(5)*	(4)	(5)	(3)	(2)*	2	(1)
Income tax expense (benefit)	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(17,843)	(17,472)	(16,095)*	(20,311)	(21,254)	(21,528)	(20,772)*	(23,516)	(25,005)
Earnings per share, basic USD per share	(22.00)	(0.92)	—	(0.83)	(0.87)	(0.88)	(0.85)*	(0.95)	(0.63)
Earnings per share, diluted USD per share	(22.00)	(0.92)	—	(0.83)	(0.87)	(0.88)	(0.85)*	(0.95)	(0.63)
Weighted average shares, basic thousands of shares	811	18,897	—	24,342	24,379	24,482	24,571*	24,678	39,413
Weighted average shares, diluted thousands of shares	811	18,897	—	24,342	24,379	24,482	24,571*	24,678	39,413

† Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (ARTV's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	34,248	55,881	40,235	30,401	28,468	25,508	26,701	20,955	301,454
Short-term investments	12,308	90,750	145,193	135,562	113,897	97,460	81,307	65,827	47,940
Accounts receivable	569	569	0	—	—	—	—	—	—
Prepaid and other current assets	1,732	3,233	3,057	3,807	6,671	6,477	4,591	1,958	2,741
Total current assets	49,749	150,565	188,631	170,004	149,066	129,524	112,666	88,740	352,276
Property and equipment, net	7,315	6,857	6,370	7,057	6,886	6,981	6,618	6,216	5,671
Right-of-use asset	15,129	14,376	13,794	13,482	12,709	11,262	10,525	9,884	9,236
Total assets	75,912	225,596	209,581	191,263	169,391	148,862	130,940	105,955	368,633
Accounts payable	823	1,215	1,121	2,036	1,215	848	355	2,286	1,386
Accrued liabilities	6,214	8,344	7,392	6,375	5,838	7,026	9,600	5,559	9,896
Total current liabilities	10,827	13,292	12,253	12,204	10,768	11,119	13,087	10,880	14,581
Lease liability, non-current	11,869	11,160	10,570	10,265	9,582	8,519	7,883	7,228	6,550
Total liabilities	50,596	24,600	22,940	22,480	20,350	19,638	20,970	18,108	21,131
Accumulated deficit	(213,117)	(230,589)	(246,684)	(266,995)	(288,249)	(309,777)	(330,549)	(354,065)	(379,070)
Total stockholders' equity	(191,097)	200,996	186,641	168,783	149,041	129,224	109,970	87,847	347,502
Total liabilities and equity	75,912	225,596	209,581	191,263	169,391	148,862	130,940	105,955	368,633
Common shares outstanding (cover page) thousands of shares	24,287	24,289	24,363	24,363	24,426	24,545	24,717	24,717	48,890

† Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (ARTV's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(17,843)	(17,472)	(16,095)*	(20,311)	(21,254)	(21,528)	(20,772)*	(23,516)	(25,005)
Stock-based compensation	1,483*	1,907*	2,184*	2,052	1,549*	1,631*	1,589*	1,593	1,865*
Depreciation and amortization	603*	627*	614*	628	641*	662*	666*	666	692*
Net cash from operating activities	(13,685)*	(11,611)*	(14,650)*	(19,841)	(22,983)*	(19,201)*	(14,726)*	(20,950)	(20,355)*
Purchases of property and equipment	464*	96*	64*	511	1,055*	600*	421*	242	415*
Net cash from investing activities	1,349*	(130,628)*	(966)*	9,971	21,122*	16,278*	16,040*	15,316	17,585*
Proceeds from issuing common stock	—	—	0*	—	—	—	year only	—	—
Net cash from financing activities	—	163,872*	(30)*	239	(72)*	(37)*	(121)*	(112)	283,269*
Net change in cash	(13,952)*	21,633*	(15,646)*	(9,631)	(1,933)*	(2,960)*	1,193*	(5,746)	280,499*

† Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Artiva Biotherapeutics	301,454	not reported	(20,355)*	48.9M	17.2 quarters	Q2 FY26 10-QJun 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
X4 Pharmaceuticals	195,095	2,400	(20,788)*	99.1M	9.4 quarters	Q2 FY26 10-QJun 30, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.